US FDA approves Eyenovia`s eye drug, Formosa Pharma says
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália
Zhejiang Yongtai`s Generic Clobetasol Propionate Receives Approval in the U.S.
Enforcement Report - Week of June 7, 2023
Enforcement Report - Week of February 1, 2023
Salvat, the international laboratory that has developed and owns Cristalmina, Gama Relive, Tebarat and Cetraxal products, has submitted the NDA documentation for a new drug application to the U.S. Food and Drug Administration (FDA) for approval of Clobetasol, the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in patients undergoing eye surgery.
Enforcement Report - Week of April 20, 2022
Enforcement Report - Week of March 30, 2022
Solaris Pharma's Generic Clobetasol Propionate Receives Approval in the U.S.
Enforcement Report - Week of January 26, 2022